A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N, N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers.

Front Pharmacol · 2021 · PMC8667866 · PMID 34912222

Europe PMC DOI

hedged sentence

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

approached significancep = .053so close (0.05 < p ≤ 0.1)

The effects of dose on ratings of Oceanic Boundlessness approached significance (F 4,17 = 2.901, p = .053, η p 2 = 0.406).

also in 8,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.